Tougher British regulations on human drug experiments triggered by last year’s disastrous “elephant man” clinical trial are driving medical research out of the UK, pharmaceutical groups have warned.

As a new regime for scrutinising high-risk drugs comes into effect this month, new data show a number of companies have delayed their trials, switched research to other countries and expressed concern that longer and tighter scrutiny will push more away.